Apex Capital Management’s Biogen BIIB Stock Holding History

Apex Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$702K	Sell	2,697 -115	-4%	-$30.4K	0.02%	214
2015 Q4	$861K	Buy	2,812 +431	+18%	+$124K	0.02%	183
2015 Q3	$695K	Sell	2,381 -907	-28%	-$300K	0.02%	190
2015 Q2	$1.33M	Buy	3,288 +895	+37%	+$359K	0.03%	179
2015 Q1	$1.01M	Sell	2,393 -10	-0.4%	-$3.94K	0.02%	184
2014 Q4	$816K	Buy	2,403 +10	+0.4%	+$3.23K	0.02%	188
2014 Q3	$792K	Buy	2,393 +893	+60%	+$294K	0.02%	186
2014 Q2	$473K	Hold	1,500	–	–	0.01%	226
2014 Q1	$459K	Buy	+1,500	New	+$476K	0.02%	214

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Apex Capital Management's BIIB Position: Q1 2016 in Review

Apex Capital Management reduced its Biogen (BIIB) stake by 4.1% in Q1 2016, selling an estimated $30.4K and leaving 2,697 shares worth $702K. The position accounts for 0.02% of the portfolio, ranked #214.

Apex Capital Management first reported a position in BIIB in Q1 2014 and has held it in 9 quarters since. The position peaked at $1.33M in Q2 2015. 947 funds tracked by Wall St. Rank hold BIIB as of Q1 2016.

Apex Capital Management held 2,697 shares of Biogen worth $702K as of Q1 2016.
Apex Capital Management sold 115 Biogen shares in Q1 2016, an estimated $30.4K.
Biogen made up 0.02% of Apex Capital Management's portfolio in Q1 2016, its #214 holding.
Apex Capital Management first reported a position in Biogen in Q1 2014 and has held it in 9 quarters since.
Apex Capital Management's Biogen position peaked at $1.33M in Q2 2015.
947 funds tracked by Wall St. Rank held Biogen as of Q1 2016.

Based on Apex Capital Management's 13F filing for Q1 2016, filed 27 Apr 2016.